Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,049–1,056 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY III) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY III) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY II) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY II) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. BXCL701 plus KEYTRUDA Metastatic castration-resistant prostate cancer (mCRPC) Phase 2 Trial Planned oral and intravenous Oncology
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (PLACIDITY) Agitation associated with delirium Phase 2 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY III) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric
BioXcel Therapeutics Inc. Dexmedetomidine (BXCL501) - (TRANQUILITY II) Agitation associated with Alzheimer’s Disease Phase 3 Ongoing Sublingual Psychiatric